Annual Report Acceleron Pharma • Cambridge, MA
Establish CRO network for method development, tech transfer, testing and stability studies supporting our drug substance and drug product CMO network to enable Ph3 and commercial drug supplies.
Acceleron Pharma
- Employees: 130
- Market Cap: $2.02 billion
- Revenue: $13.24 million
- 5 Year Trend: 2.4%
- Net Income: $-91.32 million
- Stock: XLRN
Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Boston, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels. John Knopf, Jasbir Seehra, Tom Maniatis, Mark Ptashne and Wylie Vale formed the company in Cambridge, Massachusetts. Wikipedia
Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Boston, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels. John Knopf, Jasbir Seehra, Tom Maniatis, Mark Ptashne and Wylie Vale formed the company in Cambridge, Massachusetts. Wikipedia
- Employees: 130
- Market Cap: $2.02 billion
- Revenue: $13.24 million
- 5 Year Trend: 2.4%
- Net Income: $-91.32 million
- Stock: XLRN